Add to ORKGCOST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHIN
Abstract Objective: To evaluate long-run cost-effectiveness in a Swedish setting for liraglutide com...
Back ground: Diabetes mellitus is a chronic lifelong disease, requiring long term expensive treatmen...
Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescri...
Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to me...
Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescri...
Background: With the available evidence of early combined oral drug therapies being more effective i...
Objective: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel sodium- glucose co...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
ObjectiveTo systematically estimate and compare the effectiveness and cost-effectiveness of the gluc...
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...
Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...
This study aimed to assess the costs and benefits of three alternative second-line treatment strateg...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...
Diabetes mellitus (DM) requires long-term therapy. Selection of the right therapy was very important...
Abstract Objective: To evaluate long-run cost-effectiveness in a Swedish setting for liraglutide com...
Back ground: Diabetes mellitus is a chronic lifelong disease, requiring long term expensive treatmen...
Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescri...
Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to me...
Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescri...
Background: With the available evidence of early combined oral drug therapies being more effective i...
Objective: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel sodium- glucose co...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
ObjectiveTo systematically estimate and compare the effectiveness and cost-effectiveness of the gluc...
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...
Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...
This study aimed to assess the costs and benefits of three alternative second-line treatment strateg...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...
Diabetes mellitus (DM) requires long-term therapy. Selection of the right therapy was very important...
Abstract Objective: To evaluate long-run cost-effectiveness in a Swedish setting for liraglutide com...
Back ground: Diabetes mellitus is a chronic lifelong disease, requiring long term expensive treatmen...
Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescri...